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Abstract
Rationale—Mitogen-activated protein kinase (MAPK) pathways provide a critical connection
between extrinsic and intrinsic signals to cardiac hypertrophy. Extracellular signal-regulated
protein kinase 5 (ERK5), an atypical MAP kinase is activated in the heart by pressure overload.
However, the role of ERK5 plays in regulating hypertrophic growth and hypertrophy-induced
apoptosis is not completely understood.
Objective—Herein, we investigate the in vivo role and signaling mechanism whereby ERK5
regulates cardiac hypertrophy and hypertrophy-induced apoptosis.
Methods and Results—We generated and examined the phenotypes of mice with
cardiomyocyte-specific deletion of the erk5 gene (ERK5cko). In response to hypertrophic stress,
ERK5cko mice developed less hypertrophic growth and fibrosis than controls. However, increased
apoptosis together with upregulated expression levels of p53 and Bad were observed in the mutant
hearts. Consistently, we found that silencing ERK5 expression or specific inhibition of its kinase
activity using BIX02189 in neonatal rat cardiomyocytes (NRCMs) reduced myocyte enhancer
factor 2 (MEF2) transcriptional activity and blunted hypertrophic responses. Furthermore, the
inhibition of MEF2 activity in NRCMs using a non-DNA binding mutant form of MEF2 was
found to attenuate the ERK5-regulated hypertrophic response.
Conclusions—These results reveal an important function of ERK5 in cardiac hypertrophic
remodeling and cardiomyocyte survival. The role of ERK5 in hypertrophic remodeling is likely to
be mediated via the regulation of MEF2 activity.
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Introduction
Cardiac hypertrophy is a virtually universal prerequisite for the development of heart failure.
In response to acute or chronic insults the heart initially develops hypertrophic growth.
However, sustained stress causes chamber dilation, interstitial fibrosis, and myocyte
apoptosis, eventually leading to heart failure or sudden death from arrhythmias. Numerous
signaling pathways including Mitogen-Activated Protein (MAP) kinases are implicated in
mediating the process of cardiac hypertrophy and hypertrophy-induced cardiomyocyte
apoptosis1. In the heart, all four classes of MAP kinases are activated through either
mechanical overload or neurohumoral stimulation2. However, our understanding of the
critical role of individual MAPK in various aspects of hypertrophic remodeling remains
fragmented and in many cases controversial.
Extracellular signal-regulated protein kinase 5 (ERK5) is an atypical MAP kinase, also
known as big MAPK (BMK1), as it is more than twice the size of the other MAPKs owing
to a very large C-terminal domain3. It is suggested that the role of this unique C-terminal tail
is to regulate myocyte enhancer factor 2 (MEF2) transcriptional activity and ERK5 sub-
cellular localization3, 4. Upon exposure to various stimuli, ERK5 is activated by
phosphorylation downstream of MEK55. An important step in deciphering the function of
ERK5 is to identify its downstream targets and MEF2A, C and D are among the best-
characterized substrates of ERK54, 5. Analogous to many MAP kinases, ERK5 plays an
important role in cell survival, cell proliferation and differentiation. The discovery that
ERK5 is an important contributor to cell survival has increased interest in this signaling
pathway. In sympathetic neurons, ERK5 is required to mediate the survival response to
nerve growth factor by suppressing the expression of Bad and Bim6. The analysis of mice
with an endothelial-specific deletion of ERK5 provides physiological evidence that ERK5 is
essential for the survival of endothelial cells via the activation of MEF27. Moreover, recent
studies have demonstrated that ERK5 activation prevents cardiomyocyte apoptosis, likely
through the inhibition of a feedback loop of phosphodiesterase 3A/inducible cAMP early
repressor8. Apart from its role in cardiomyocytes survival, ERK5 has also been implicated in
regulating cardiac hypertrophy9, 10.
ERK5 can be activated in the heart by pressure overload, and by hypertrophy-stimulating
factors including LIF (leukemia inhibitory factor), adrenergic agonists, oxidative and
osmotic stresses in cultured cardiomyocytes11, 12. However, previous studies of transgenic
mice with cardiac-specific over-expression of activated MEK5 provided conflicting results.
Decompensated eccentric hypertrophy with no cardiomyocte apoptosis was observed in
MEK5β transgenic mice, which is in stark contrast to the normal cardiac function and
morphology found in MEK5α transgenic mice12, 13. Upon hypertrophic stress, MEK5α
transgenic mice develop hypertrophic growth to a similar degree to controls but with
reduced apoptosis and better cardiac function8. Regarding the capacity of activating ERK5,
we have demonstrated that MEK5β is an active enzyme while MEK5α is a stronger activator
due to its higher affinity for ERK514. In contrast, Cameron et al. proposed that MEK5β is3 a
dominant negative variant that can suppress ERK5 signaling15. Moreover, expression of
MEK5α has been suggested to be restricted to brain and liver, whereas MEK5β is
ubiquitously expressed16. Given these contradictions emerging from MEK5 studies, it is
necessary to investigate the function of ERK5 in the heart using cardiomyocyte-specific
ERK5 deletion mice (ERK5cko), a physiologically-relevant model compared to the
overexpressing transgenic lines. Hayashi et al. have previously generated and described a
cardiomyocyte-specific ERK5 deletion mouse model7. In concordance with their
observation, we also found ERK5cko mice (generated in our lab) were viable, fertile and
appeared normal, suggesting the specific ablation of erk5 in cardiomyocytes alone does not
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affect cardiac development. To characterize the role of ERK5 in cardiac hypertrophy we
subjected ERK5cko mice to hypertrophic stimuli, the mutant mice developed less
hypertrophic growth and fibrosis compared to controls (ERK5f/f), also increased apoptosis
with upregulated expression of p53 and Bad were observed in the mutant heart.
Consistently, we found that silencing ERK5 expression or specific inhibition of its kinase
activity using a novel compound BIX02189 in neonatal rat cardiomyocytes (NRCMs)
reduced MEF2 transcriptional activity and blunted the hypertrophic response. Moreover, the
inhibition of MEF2 activity in NRCMs using a non-DNA binding mutant form of MEF2C
was found to diminish the ERK5-regulated hypertrophic response. These results clearly
reveal an important function of ERK5 in stress-induced cardiac hypertrophic remodeling and
cardiomyocyte survival.
Materials and Methods
Induction of Cardiac Hypertrophy
Cardiac hypertrophy was induced by transverse aortic constriction (TAC) or chronic
infusion of isoproterenol (ISO, Sigma-Aldrich) at 10mg/ml for 7 days in 8–10 week old
male ERK5f/f and ERK5cko mice as previously described17.
An expanded methods section is available in the Supplement Data.
Results
Characterization of ERK5cko Mice
Using α myosin heavy chain (αMHC) promoter driven-Cre transgenic mice, we generated
ERK5cko mice. Normal levels of ERK5 mRNA were present in brain and liver, whereas
ERK5 mRNA was significantly reduced (approximately 86%) in the mutant ventricle
(Supplement Figure IA). Immunoblot analysis of ventricular extracts from ERK5cko mice at
8 weeks old showed more than 80% deletion of ERK5 protein (Supplement Figure IB). It
was evident that ablation of ERK5 was specific to the heart since protein levels of ERK5
were equivalent in brain, liver and skeletal muscle from both ERK5cko and ERK5f/f mice
(Supplement Figure IB). The absence of ERK5 in the heart did not cause any compensatory
changes in the protein levels of other MAPKs, such as ERK1/2, JNK, p38 and MEK5
(Supplement Figure IC). Furthermore, cardiac structure and contractile function were
examined by histological analysis and echocardiography, respectively, and no differences
were found between the two genotypes (data not shown).
ERK5cko Mice Displayed Less Cardiac Hypertrophic Remodeling Upon Pressure Overload
To determine whether ERK5 is required for pressure overload-induced cardiac hypertrophic
remodeling, ERK5f/f and ERK5cko mice were subjected to pressure overload stimulation by
Following 1 week of TAC, ERK5f/f mice showed a 34% increase in heart weight/tibia length
(HW/TL). In contrast, ERK5cko mice showed only a 23% increase in HW/TL (Figure 1A
and 1B). Consistent with these results, greater cross-sectional area of cardiomyocytes was
observed in ERK5f/f-TAC mice (280.05±6.27 μm2), in comparison to 256.51±8.03 μm2 in
ERK5cko-TAC mice (Figure 1C). Pressure overload-induced hypertrophy is often
accompanied by interstitial fibrosis. Based on Masson’s trichrome staining, less ventricular
fibrosis was seen in ERK5cko-TAC hearts (Figure 1D). Furthermore, cardiac structure and
function were assessed by echocardiography. In response to TAC, ERK5cko mice showed a
significant reduction in end-diastolic left ventricular posterior wall thickness (dPW)
compared with the control group. Meanwhile, we also found in the mutant hearts a trend
towards a decrease in fractional shortening (FS %), and a markedly slowed aorta maximum
velocity (Ao Vmax), which is a sign of contractile dysfunction (Table 1). Fetal gene
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activation is a hallmark of hypertrophic remodeling. Shown in Figure 2, upregulation of the
transcripts of the hypertrophic gene markers atrial natriuretic peptide (ANP), brain
natriuretic peptide (BNP), skeletal α-actin (Acta1), and β myosin heavy polypeptide (Myh7)
was remarkably blunted in the mutant hearts following TAC; we also found the mRNA level
of α myosin heavy polypeptide (Myh6) was compromised in the mutant hearts (Figure 2).
Consistent with Masson’s trichrome staining, the fibrosis marker genes connective tissue
growth factor (Ctgf), procollagen type I, α2 (Col1α2) and procollagen type III, a3 (Col3α1)
were significantly downregulated in ERK5cko-TAC mice compared with the controls
(Figure 2). Finally, we investigated the activation of ERK5 and an array of hypertrophic
regulators such as ERK1/2, PKB, p38 and JNK after TAC. ERK5 was activated by TAC in
ERK5f/f hearts but not in ERK5cko hearts, meanwhile there was no difference observed in
the activation of other hypertrophic regulators between the two genotypes although all were
activated following TAC (Figure 3). These results suggest that the blunted hypertrophic
response in the mutant mice is likely due to the absence of ERK5 in the heart.
ERK5cko Cardiomyocytes Were More Vulnerable Under Hypertrophic Stress
Sustained hypertrophic stress causes cardiomyocyte apoptosis which contributes to the
transition of pathological hypertrophy to heart failure. To determine the effect of ERK5 on
cardiomyocyte viability under hypertrophic stress TUNEL staining and caspase 3 activity
assays were performed to detect cardiomyocyte apoptosis. We observed increased TUNEL-
positive nuclei along with enhanced caspase 3 activity in the mutant hearts following TAC
(Figure 4A–C). In accordance with this finding, ERK5cko-TAC mice showed augmented
protein levels of Bad and p53, whereas the expression level of Bcl-2 was comparable in both
genotypes (Figure 4D). A recent study demonstrated a protective role of ERK5 in
sympathetic neurons through the phosphorylation of Ca2+/cAMP response element-binding
protein (CREB), thereby suppressing the transcription of Bad6. However, we did not observe
any change in the protein level and phosphorylation status of CREB in the mutant hearts
(Figure 4D). Furthermore, in the two sham groups, no difference was detected in expression
levels of these apoptosis-associated proteins (Supplement Figure II). Together, these data
suggest that ERK5 is required for cardiomyocyte survival in response to pressure overload
by suppressing the mitochondrion-dependent apoptotic pathway.
Prolonged Pressure Overload Caused Cardiac Dysfunction in ERK5cko Mice
To further examine whether the lack of ERK5 in cardiomyocytes predisposes mice to heart
failure following long-term pressure overload stimulation, ERK5f/f and ERK5cko mice were
subjected to 5 weeks of TAC. Likewise, 5 weeks of TAC also caused compromised HW/TL
ratio, smaller myocyte cross-sectional areas, and less fibrosis in ERK5cko mice compared
with the controls (Figure 5A–C). Analysis of gene expression profile showed that mRNA
levels of ANP, BNP, Myh7, Acta1, Ctgf, Col1α2 and Col3α1 were significantly lower in
ERK5cko-TAC hearts (Supplement Figure III). Furthermore, a much more pronounced
apoptosis was detected in ERK5cko cardiomyocytes (Figure 5D). Interestingly, we observed
detrimental changes in ERK5cko cardiac function after 5 weeks of TAC, which was evident
by significant decreases in FS % and AoVmax (Figure 5E). Collectively, these data
demonstrate the functional importance of ERK5 in protecting the heart from failure
following chronic pressure overload stimulation.
ERK5cko Mice Showed an Attenuated Cardiac Hypertrophic Response to Chronic β-
adrenergic Stimulation
We next investigated whether ERK5 is required for cardiac hypertrophic remodeling in
response to chronic β-adrenergic stimulation. After 7 days administration of isoproterenol,
ERK5cko mice developed blunted hypertrophy reflected by a 32% increase in HW/TL,
compared with the controls (48%). Consistently, ERK5cko mice showed a reduction in
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cross-sectional area (254.35±3.37 μm2), compared with ERK5f/f mice whose cardiomyocyte
cross-sectional area was 306.7±5.4 μm2 after the ISO-treatment (Supplement Figure IV).
Interstitial fibrosis was also more noticeable in the control hearts (Supplement Figure IV).
Furthermore, the transcript levels of ANP and BNP were found to be remarkably elevated in
the ERK5f/f hearts, compared with the mutant hearts (Supplement Figure IV). These results
indicate that ERK5 regulates cardiac hypertrophic remodeling not only by pressure
overload, but also by chronic β-adrenergic stimulation.
The Knockdown of ERK5 or Inhibition of Its Activation Suppressed MEF2 Transcriptional
Activity and Promoted Apoptosis in NRCMs
MEF2 transcription factor is a key regulator of pathological cardiac hypertrophy18. Led by
the result that the transcript levels of Ctgf, Myh6 and Acta1 (known to be downstream
targets of MEF218–20) were compromised in ERK5cko-TAC hearts we further examined
whether MEF2 transcriptional activity was mediated by ERK5 in cardiomyocytes in
response to hypertrophic stimuli. Using the MEK5/ERK5 selective inhibitor (BIX02189,
10μM), ERK5 phosphorylation was specifically inhibited which led to attenuated MEF2
activity in NRCMs following ISO treatment (Figure 6A, 6B). To corroborate this result,
NRCMs were transfected with the reporter plasmid pG5E1bLuc together with a construct
encoding Gal4, Gal4-MEF2A, or Gal4-MEF2D. As expected, reduced MEF2 transcriptional
activity was detected in BIX02189-treated NRCMs after ISO stimulation (Supplement
Figure V). In parallel, using an siRNA method we specifically suppressed endogenous
ERK5 expression by 83% in NRCMs; a similar inhibitory effect on MEF2 transcriptional
activity was also found (Figure 6C, 6D and Supplement Figure V). Furthermore, siERK5-
treated NRCMs showed an impaired hypertrophic response which was evident by decreased
mRNA levels of ANP and Acta1, and diminished protein synthesis (Figure 7A, 7B). To
further critically examine the effect of MEF2 on ERK5 mediated-hypertrophic response, an
adenovirus containing a non-DNA binding mutant form of MEF2C (Ad-MEF2C-R3T) was
used to inhibit MEF2 activity8, 21. After ISO stimulation, we observed an increased rate of
protein synthesis and elevated transcript level of ANP in Ad-ERK5-infected NRCMs;
however, such hypertrophic increases were appreciably blunted by the co-infection of Ad-
MEF2C-R3T (Figure 7C–E). Combined, these data strongly suggest that MEF2 acts
downstream of ERK5 to promote a hypertrophic response. Lastly, we evaluated the effect of
ERK5 knockdown or the inhibition of its kinase activation on apoptosis in NRCMs.
Consistent with apoptosis results obtained from ERK5cko-TAC mice, increased apoptosis
was detected in siERK5-treated or BIX02189-treated NRCMs upon exposure to the
proapoptotic agent sorbitol, which confirms the protective role of ERK5 in cardiomyocytes
(Supplement Figure VI).
Discussion
The major finding of this study is that ERK5 plays an important role in promoting
hypertrophic remodeling and cardiomyocyte survival. In the absence of ERK5, hypertrophic
growth, interstitial fibrosis and fetal gene reactivation were profoundly compromised;
meanwhile increased cardiomyocyte death was seen following hypertrophic stimuli. Further
studies in NRCMs treated with either siERK5 or a novel ERK5 kinase inhibitor (BIX02189)
have provided clear evidence that MEF2 is a critical component downstream of the ERK5
signaling pathway in regulating hypertrophic response.
The role of ERK5 in hypertrophic remodeling
ERK5 is implicated in the induction of cardiac hypertrophy and heart failure in humans10,
22; however, our understanding of its involvement in various aspects of cardiac remodeling
is limited, and in some cases controversial. For example, previous studies using transgenic
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mice with cardiac-specific overexpression of activated MEK5 provided conflicting results8,
12, 13, which can be partially explained by the fact that different isoforms (α, β form) of
MEK5 were used to generate the transgenic lines. An additional explanation is the
transgenic approach, as phenotypes observed from transgenic mouse models are largely
associated with the copy number of overexpressed genes. With respect to the fact that ERK5
may exert actions independent of its kinase activity23, it was hoped that the analysis of
ERK5cko mice would generate more direct information on the specific contribution of ERK5
in the heart. In the present study, phenotypes observed from ERK5cko mice were reminiscent
of observations in MEF2D-null mice19; they also demonstrated blunted hypertrophic growth
and fibrosis, together with the downregulation of mRNA levels of MEF2-regulated genes. In
line with these observations, enhanced hypertrophy was seen in mice with cardiac-specific
overexpression of MEF2A after TAC20. Interestingly, ERK5 and p38 MAPK are able to
phosphorylate and activate MEF2A and MEF2C, whereas MEF2D is a specific substrate of
ERK53, 5. Of note, the major MEF2 isoforms in the adult heart are MEF2A and MEF2D,
which participate in mediating different aspects of pathological cardiac signaling19, 20.
Recent studies in conventional and cardiomyocyte-specific p38 knockout mouse models
suggest that p38 does not promote cardiac hypertrophy and may, in fact, prevent it24, 25.
Considering the above evidence, MEF2 is most likely to perform as a hypertrophic player
downstream of ERK5, rather than p38. Furthermore, responding to isoproterenol
stimulation, a diminution was found in MEF2 transcriptional activity in NRCMs in which
ERK5 was exclusively knocked down or its kinase activation was specifically inhibited. In
addition to this, reduced protein synthesis and downregulated mRNA levels of ANP and
Acta1 were detected in siERK5-treated NRCMs following isoproterenol treatment.
Moreover, the finding that the inhibition of MEF2 activity was able to attenuate the ERK5-
regulated hypertrophic response strengthens the notion that MEF2 acts downstream of
ERK5 in regulating hypertrophy.
CTGF is a key mediator of tissue fibrosis, which is predominantly expressed in fibroblasts;
however, during cardiac remodeling it is also secreted by cardiomyocytes26, 27. Several lines
of evidence indicate the important role of MEF2 in regulating CTGF expression19, 20, 28. In
the present study, the decreased Ctgf mRNA level along with less interstitial fibrosis were
seen in ERK5cko-TAC hearts, thus it is plausible to propose that absence of ERK5 in
cardiomyocytes is likely responsible for such phenotypes via downregulated MEF2 activity.
Taken together, these data provide unequivocal evidence that ERK5 is responsible for
controlling MEF2 activity in different aspects of hypertrophic remodeling.
In parallel, we also investigated the activation of a number of hypertrophic regulators
following TAC stress, including ERK1/229, p3824, JNK17 and PKB30. However, we did not
observe any difference in their activities between the two genotypes; this underpins the
notion that ERK5 is an important character in mediating hypertrophic remodeling. It is
worth noting that residual hypertrophic growth seen in ERK5cko-TAC mice is likely due to
the activation of ERK1/2 and PKB, which are known as promoters of hypertrophy29, 30.
ERK5 is required for cardiomyocyte survival
Apart from the altered hypertrophic response, we also detected an increase in apoptotic
cardiomyocytes with enhanced Bad and p53 protein levels in TAC treated-mutant hearts,
indicating that ERK5 prevents hypertrophy induced-cardiomyocyte loss. The ability of
ERK5 to protect endothelial cells from shear stress via inhibition of Bad activation was
established by Pi et al31. Furthermore, evidence has been provided that ERK5 is required to
mediate neuronal survival by suppressing Bad expression via a mechanism dependent on
CREB transcriptional activity6. Consistent with this study, we also found upregulated Bad
expression in ERK5cko-TAC cardiomyocytes, although we did not observe any change in
the protein level and phosphorylation status of CREB. CREB is a pro-survival transcription
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factor which either acts as an activator for increasing Bcl-2 expression or as a repressor of
Bad expression6, 32. Interestingly, cardiomyocyte-specific inactivation of CREB did not
cause any increase in apoptosis at basal level32; nevertheless, further studies are required to
address the role of CREB in protecting cardiomyocytes following stress. Prolonged pressure
overload is known to cause an accumulation of p53, which is a pivotal mediator of
apoptosis33, 34. It has been demonstrated that p53 is able to induce a number of Bcl-2 family
genes, including Bad34, 35. Thus, the upregulated p53 expression found in ERK5cko-TAC
hearts is proposed to be responsible for the increased level of Bad. It is also worth noting
that impaired contractility seen in the mutant hearts after TAC is very likely attributed to the
increased apoptosis. Although the actual rate of apoptosis is low, it is, however, reasonable
to believe that this level of apoptosis is sufficient to cause cardiac dysfunction36. As
discussed, it is suggested that ERK5 is necessary for protecting cardiomyocyte against
hypertrophic stress and for determining cardiac function during hypertrophic remodeling.
Novel pharmacological inhibitors of the MEK5/ERK5 pathway
ERK5 is one of the least studied MAPK subfamilies due, in part, to the lack of biological/
pharmacological tools, including specific inhibitors. Recently, the MEK5/ERK5 selective
inhibitors, BIX02188 and BIX02189 have been identified. BIX02189 is demonstrated to
have greater potency in inhibiting ERK5 activity than BIX0218837, 38. In the present study,
by applying BIX02189 to NRCMs, we detected that ERK5 phosphorylation was specifically
blocked without affecting the activation of other MAP kinases; MEF2 transcriptional
activity was also impaired. Thus, for the first time, our results provide important information
regarding the effect of BIX02189 in cardiomyocytes. It has been demonstrated that ERK5 is
required for tumor growth due to its essential role in the development of tumor
vasculature39. Selectively targeting the ERK5 pathway by pharmacological compounds is
thought to be a promising approach for treating cancers. Although, the availability of
selective MEK5/ERK5 inhibitors may shed light in developing such a therapeutic strategy, it
must nevertheless be considered that ERK5 has a role in many other tissues. Further
investigation of these MEK5/ERK5 inhibitors in vivo under basal and various stress
conditions is certainly required.
In conclusion, the present study provides convincing evidence that clarifies the in vivo role
of ERK5 in the heart. ERK5 regulates hypertrophic remodeling and protects cardiomyocyes
from hypertrophic stress mostly likely by regulating the MEF2 transcription activity. The
recognition of the functional importance of ERK5 in the heart provides invaluable
information regarding the possible beneficial or adverse effects of new therapeutic
strategies.
An expanded discussion is available in online data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Non-standard Abbreviations and Acronyms
αMHC α myosin heavy chain
Actal skeletal α-actin
Ad adenovirus
ANP atrial natriuretic peptide
Ao Vmax , aorta maximum velocity
BMK1 big mitogen-activated protein kinase1
BNP brain natriuretic peptide
Camp cyclic adenosine monophosphate
Col1α2 procollagen type I, α2
Col3α1 procollagen type III, α3
CREB Ca2+/cAMP response element-binding protein
Ctgf connective tissue growth factor
dIVS end-diastolic interventricular septal wall thickness
dPW end-diastolic left ventricular posterior wall thickness
ERK5 extracellular signal-regulated protein kinase 5
FS fractional shortening
HIF-1α hypoxia inducible factor 1α
HW/TL heart weight/tibia length
ISO isoproterenol
LIF leukemia inhibitory factor
LVEDD diastolic left ventricular internal dimension
LVESD systolic left ventricular internal dimension
MAPK mitogen-activated protein kinase
MEF2 myocyte enhancer factor 2
MEK5 MAPK/ERK kinase 5
Myh6 α myosin heavy polypeptide
Myh7 β myosin heavy polypeptide
NRCM neonatal rat cardiomyocyte
TAC transverse aortic constriction
TUNEL Terminal-Deoxynucleotidyl-Transferase-Mediated-dUTP-Nick-End-Labeling
VEGF vascular endothelial growth factor
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Figure 1.
Less response to 1 week TAC induced-hypertrophy in ERK5cko mice. (A) Hematoxylin &
eosin staining of heart cross-sections (scale bar: 20μm). (B) HW/TL ratios of ERK5f/f and
ERK5cko mice were calculated following TAC or sham operation, n=7 to 9 per group. (C)
The mean cross-sectional areas of cardiomyocytes from two genotypes were measured, n=5.
(D) Masson’s trichrome-staining of cross-sections shows less interstitial fibrosis in ERK5cko
hearts. Arrows indicate areas of fibrosis. Quantification of the relative area of fibrosis is
expressed as percentage of the fibrosis area in the microscope views, n=7. Data are
presented as mean ± SEM.
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Figure 2.
Quantitative real-time PCR analyses of gene markers associated with hypertrophy and
fibrosis after 1 week TAC. The data are derived from three independent experiments
performed in triplicate and are normalized to the GAPDH content, n=3 to 5 per group. Data
are presented as mean ± SEM.
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Figure 3.
Analysis of hypertrophic regulators in ERK5cko-TAC hearts. Protein extracts from ERK5f/f
and ERK5cko hearts subjected to TAC or sham operation were examined by immunoblotting
for total ERK5, ERK1/2, PKB, p38 and JNK expression, as well as their phosphorylation
levels using specific antibodies. The results suggest that blunted hypertrophic response in
the mutant mice is specifically due to the absence of ERK5 in the heart.
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Figure 4.
ERK5 is required for cardiomyocyte survival in response to hypertrophic stress. (A)
Increased apoptosis in ERK5cko ventricular myocardium after 1 week TAC was detected by
TUNEL assay (scale bar: 50μm). Triple staining was performed: TUNEL (green), Hoechst
(blue), α-actinin (red). Arrows point to TUNEL-positive nuclei. (B) The bar graph
summarizes the percentage of TUNEL-positive nuclei in ERK5cko hearts compared with that
in control hearts, n=7 to 11 mice per group. (C) Caspase 3 activity was measured by caspase
activity assay after TAC, n=7. (D) Immunoblot analyses of protein levels of Bad, Bcl-2, p53,
CREB and phosporylation of CREB by specific antibodies. Tubulin expression is the protein
loading control. The ratios of Bad/Bcl-2 and p53/tubulin are represented by the bar graphs,
n=4 per group. Data are mean ± SEM.
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Figure 5.
Prolonged pressure overload caused diminished hypertrophic response and cardiac
dysfunction in ERK5cko mice. (A) HW/TL ratios of ERK5f/f and ERK5cko mice following 5
weeks TAC or sham operation. (B) Quantification of the mean cross-sectional areas of
cardiomyocytes from two genotypes. (C) Quantification of interstitial fibrosis induced by
TAC. (D) TUNEL-positive nuclei in ERK5cko hearts were significantly more than that in the
controls after 5 weeks of TAC. (E) Echocardiography assessment (FS %, AoVmax)
demonstrated impaired cardiac function in ERK5cko mice. n=7 to 9 per group. Data are
presented as mean ± SEM.
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Figure 6.
ERK5 is required for mediating MEF2 activity in hypertrophic cardiomyocytes. (A)
Immunoblot analyses of expression and phosphorylation levels of ERK5, ERK1/2, p38 and
JNK in BIX02189 treated-NRCMs. (B) NRCMs were infected with Ad-MEF2-Luc for 24h
prior to the incubation of BIX02189. After 2h incubation with the inhibitor, the MEF2
transcriptional activity was measured by the luciferase reporter assay system following ISO
stimulation. (C) NRCMs were transfected with ERK5 siRNA or negative control siRNA. At
72h after transfection, cell lysates were prepared for analysis of ERK5 protein level by
immunoblotting. MEK5 and ERK1/2 protein levels were also examined to determine the
specificity of ERK5 knockdown. (D) The MEF2 transcriptional activity was measured in
siRNA-treated NRCMs following ISO treatment. n=6 per group. Data are mean ± SEM.
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Figure 7.
The critical role of MEF2 in ERK5-mediated hypertrophy. (A) Quantitative real-time PCR
analyses of hypertrophic gene markers in siRNA-treated NRCMs after ISO stimulation. The
data are derived from three independent experiments performed in triplicate and are
normalized to the GAPDH content, n=3. (B) [3H] Leucine incorporation was measured in
siRNA-treated NRCMs after ISO treatment, n=6. (C) Immunoblot analyses of ERK5,
MEF2C and GFP expression in adenovirual infected NRCMs. (D) NRCMs were infected
with Ad-MEF2C-R3T, Ad-ERK5 or Ad-ERK5 together with Ad-MEF2C-R3T. Transcript
level of ANP was measured after ISO treatment. (E) [3H] Leucine incorporation was
measured in NRCMs infected with indicated adenoviruses before and after ISO stimulation,
n=6. Data are mean ± SEM.
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Table 1
Echocardiographic assessment of ERK5f/f and ERK5cko mice after 1 week TAC.
sham TAC
ERK5f/f ERK5CKO ERK5f/f ERK5CKO
DPW (mm) 0.75±0.03 0.75±0.06 0.99±0.05 0.84±0.03*
DIVS (mm) 0.88±0.01 0.85±0.04 1.13±0.08 1.15±0.06
LVEDD (mm) 4.02±0.04 3.88±0.13 3.78±0.18 3.99±0.17
LVESD (mm) 2.66±0.04 2.69±0.09 2.55±0.17 2.95±0.24
FS (%) 34.1±0.5 30.4±2.1 32.8±1.9 27.1±2.9
Ao Vmax [cm/s] 63.4±5.3 62.7±2.7 65.7±4.3 56.3±2.1*
Ratio of E/A-Wave 1.15±0.09 1.26±0.17 1.43±0.21 1.44±0.13
dPW, end-diastolic left ventricular posterior wall thickness; dIVS, end-diastolic interventricular septal wall thickness; LVEDD, diastolic left
ventricular internal dimension; LVESD, systolic left ventricular internal dimension; FS, fraction shortening; Ao Vmax, aorta maximum velocity; E/
A, ratio of the E/A wave. n=7 to 9 per group, data are presented as mean ± SEM,
*
P< 0.05, ERK5cko-TAC mice versus ERK5f/f-TAC mice.
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